Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
2009 NOV 16 ... encompassing 167 patients. ISTODAX is a member of a new class of cancer drugs known as histonedeacetylase (HDAC) inhibitors and is expected to be commercially available in January ... CTCL who have failed prior systemic therapy. Additionally, the approval of a second HDAC inhibitor in cancer is very exciting and speaks to the potential for this class of compounds." ...
2009 NOV 30 ... Research (Use of a Cocktail Regimen Consisting of Soluble Galectin-1, Rapamycin and Histone Deacetylase Inhibitor May Effectively Prevent Type 1 Diabetes. Archives of Medical Research, ...
2009 NOV 30 ... used result in low yield or purity of functional hepatocytes. Valproic acid (VPA), a histone deacetylase inhibitor, has been demonstrated to facilitate the hepatic differentiation of mesenchymal stem ...
2009 NOV 9 ... govern the turnover provide important targets for the development of anti-cancer drugs. Histonedeacetylase (HDAC) inhibitors have been developed and evaluated extensively in clinical ... "Here we have examined the cellular effects of an S-substituted coenzyme A (CoA) inhibitor of histone acetylation, consisting of spermidine (Spd) linked to the S-terminus of CoA ...
2009 NOV 9 ... International Journal of Oncology (Efficacy of MS-275, a selective inhibitor of class I histone deacetylases, in human colon cancer models. International Journal of Oncology, ... aminomethyl] benzamide (MS-275) is a second generation historic deacetylase (HDAC) inhibitor with significant anti-tumor efficacy currently in clinical development. ...
2009 NOV 16 ... Protein Kinase and Akt Signaling by Vandetanib Synergistically Potentiates Histone Deacetylase Inhibitor-Induced Apoptosis in Human Glioma Cells. Journal of Pharmacology and Experimental ...
2009 NOV 16 ... or DNA binding of NF-kappa B subunits. They do, however, show reduced levels of the histonedeacetylase HDAC1, a negative regulator of basal NF-kappa B activity," wrote R.A. ... MEFs are less responsive to induction of NF-kappa B activity by trichostatin A, an HDAC inhibitor, suggesting that c-Abl might play a role in the HDAC-mediated repression of basal ...
2009 NOV 16 ... Current study results from the report, 'Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia,' have been ...
2009 NOV 30 ... their study in Biological & Pharmaceutical Bulletin (A Novel gamma-Lactam-Based Histone Deacetylase Inhibitor Potently Inhibits the Growth of Human Breast and Renal Cancer Cells. Biological & ...
2009 NOV 16 ... New investigation results, 'Expression of histone deacetylases in lymphoma: implication for the development of selective inhibitors,' are ... Journal of Haematology. According to a study from Milan, Italy, "Unselective histone deacetylase (HDAC) inhibitors are a promising novel therapy for lymphoid malignancies. However, ... and were found to be more sensitive to the growth inhibitory effects of the class I HDAC inhibitor MGCD0103," wrote A. Gloghini and colleagues, National Cancer Institute, Department of ...
2009 NOV 9 ... in the report 'Valproic acid induces functional heat-shock protein 70 via Class I histonedeacetylase inhibition in cortical neurons: a potential role of Sp1 acetylation.' ... to induce HSP70. Pre-treatment with phosphatidylinositol 3-kinase inhibitors or an Akt inhibitor attenuated HSP70 induction by VPA and other HDAC inhibitors. VPA treatment increased Sp1 ...
2009 NOV 23 ... (Significant Improvement in Cloning Efficiency of an Inbred Miniature Pig by Histone Deacetylase Inhibitor Treatment after Somatic Cell Nuclear Transfer. Biology of Reproduction, ...
2009 NOV 16 ... and found to inhibit both cancer and control cells in equal amounts. In contrast, histone deacetylase inhibitor trichostatin A, thiram, DSF, and monensin were identified as selective antineoplastic ...
2009 NOV 9 ... of HIV infection. We report here that suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor that has been approved for the treatment of cutaneous T cell lymphoma (CTCL), can ...
2009 NOV 23 ... "Noh H, Oh EY, Seo JY, Yu MR, Kim YO, Ha H, Lee HB. Histonedeacetylase-2 is a key regulator of diabetes-and transforming growth factor-beta ... tubular epithelial cells (NRK52-E), we found that trichostatin A, a nonselective HDAC inhibitor, decreased mRNA and protein expressions of ECM components and prevented EMT. Valproic ...
2009 NOV 9 ... the terminal steps, in which Ang II reprograms cardiac gene expression." "Histone deacetyltransferases (HDACs) are considered as the integrators of divergent ... of China, Harbin, Angiotensins, Angiotensin, Cardiology, Cardiomegaly, Cardiomyocyte, Deacetylase, Drugs, Enzyme Research, Experimental Medicine, Hypertrophy, Pharmaceuticals, ... HDAC2, one of Class I HDACs, and the effect of valproic acid (VPA), a nonspecific HDAC inhibitor, in the Ang II-induced cardiomyocyte hypertrophy. Primary cultures of neonatal rat ...
2009 NOV 9 ... causes a transient decrease, followed by a persistent increase, in levels of acetylated histone H3 in the nucleus accumbens, an important limbic brain region." "This ... persistent increase in H3 acetylation is associated with decreased levels of histone deacetylase 2 (HDAC2) in the nucleus accumbens. Similar effects were observed in the nucleus ... effects in the social defeat paradigm and other behavioral assays. HDAC inhibitor [N-(2-aminophenyl)-4-[N-( pyridine-3-ylmethoxy-carbonyl) aminomethyl] benzamide ...
2009 NOV 9 ... the novel proapoptotic ability of oncogenic H-Ras to increase cell susceptibility to a histone deacetylase inhibitor (HDACI) FR901228 for inducing caspase activation and selective apoptosis. Human urinary ...
2009 NOV 30 ... malignancies and lymphoma). ZOLINZA, manufactured by Merck & Co, Inc., is an oral histonedeacetylase (HDAC) inhibitor indicated for the treatment of cutaneous manifestations in ...
